Carcinogenesis, Vol. 21, No. 10, 1879-1883,
October 2000
© 2000 Oxford University Press
Carcinogenesis |
Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase
1 Department of Biochemistry, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582 and
2 Department of Biology and Frontier Research Center, Fukuoka Dental College, 2-15-1 Tamura, Sawara-ku, Fukuoka 814-0193, Japan
O6-methylguanine-DNA methyltransferase plays vital roles in preventing induction of mutations and cancer as well as cell death related to alkylating agents. Mice defective in the Mgmt gene, encoding the methyltransferase, were used to evaluate cell death-inducing and tumorigenic activities of therapeutic agents which have alkylation potential. Mgmt–/– mice were considerably more sensitive to dacarbazine, a monofunctional triazene, than were wild-type mice, in terms of survival. When dacarbazine was administered i.p. to 6-week-old mice and survival at 30 days was enumerated, LD50 values of Mgmt–/– and Mgmt+/+ mice were 20 and 450 mg/kg body wt, respectively. Increased sensitivity of Mgmt–/– mice to 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU), a bifunctional nitrosourea, was also noted. On the other hand, there was no difference in survival of Mgmt+/+ and Mgmt–/– mice exposed to cyclophosphamide, a bifunctional nitrogen mustard. It appears that dacarbazine and ACNU produce O6-alkylguanine as a major toxic lesion, while cyclophosphamide yields other types of modifications in DNA which are not subjected to the action of the methyltransferase. Mgmt–/– mice seem to be less refractory to the tumor-inducing effect of dacarbazine than are Mgmt+/+ mice. Thus, the level of O6-methylguanine-DNA methyltransferase activity is an important factor when determining susceptibility to drugs with the potential for alkylation.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Nagasubramanian, R. J. Hansen, S. M. Delaney, M. M. Cherian, L. D. Samson, S. C. Kogan, and M. E. Dolan Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure Mutagenesis, September 1, 2008; 23(5): 341 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-C. Ma, C.-C. Kuo, J.-F. Liu, L.-T. Chen, and J.-Y. Chang Transcriptional Repression of O6-Methylguanine DNA Methyltransferase Gene Rendering Cells Hypersensitive to N,N'-Bis(2-chloroethyl)-N-nitrosurea in Camptothecin-Resistant Cells Mol. Pharmacol., August 1, 2008; 74(2): 517 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Sandercock, J. N. Hahn, L. Li, H.A. Luchman, J. L. Giesbrecht, L. A. Peterson, and F. R. Jirik Mgmt deficiency alters the in vivo mutational spectrum of tissues exposed to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) Carcinogenesis, April 1, 2008; 29(4): 866 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sanada, M. Hidaka, Y. Takagi, T. Y. Takano, Y. Nakatsu, T. Tsuzuki, and M. Sekiguchi Modes of actions of two types of anti-neoplastic drugs, dacarbazine and ACNU, to induce apoptosis Carcinogenesis, December 1, 2007; 28(12): 2657 - 2663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Hansen, R. Nagasubramanian, S. M. Delaney, L. D. Samson, and M.E. Dolan Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice Carcinogenesis, May 1, 2007; 28(5): 1111 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. U. Bracker, B. Giebel, J. Spanholtz, U. R. Sorg, L. Klein-Hitpass, T. Moritz, and J. Thomale Stringent Regulation of DNA Repair During Human Hematopoietic Differentiation: A Gene Expression and Functional Analysis Stem Cells, March 1, 2006; 24(3): 722 - 730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Dolan and R. L. Schilsky Silence Is Golden: Gene Hypermethylation and Survival in Large-Cell Lymphoma J Natl Cancer Inst, January 2, 2002; 94(1): 6 - 7. [Full Text] [PDF]
|
|